Capecitabine: A review of its use in the treatment of advanced or metastatic colorectal cancer

Drugs

Volumn 61, Issue 15, 2001, Pages 2309-2326

  McGavin, Jane K ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Capecitabine; Colorectal cancer; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Tolerability

Indexed keywords

ALPHA FLUORO BETA ALANINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PACLITAXEL; PHENYTOIN; UFT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER INHIBITION; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; DRUG TUMOR LEVEL; HUMAN; METASTASIS; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

BIKINIA LE-TESTUI;

EID: 0035690103     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161150-00015     Document Type: Review

References (53)

1. Estimates of the worldwide mortality from 25 cancers in 1990
2. Estimates of the worldwide incidence of 25 major cancers in 1990
3. ABC of colorectal cancer: Epidemiology
4. Palliative chemotherapy for advanced colorectal cancer: Systematic review and meta-analysis
5. Novel oral fluoropyrimidines in the treatment of metastatic colorectal cancer
6. Fluoropyrimidines in the treatment of advanced neoplastic diseases: Role and advantages of UFT
7. The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine
8. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
9. Mechanism of action of fluoropyrimidines: Relevance to the new developments in colorectal cancer chemotherapy
10. Capecitabine: Preclinical pharmacology studies
11. Capecitabine
12. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts
13. Antitumor efficacy of capecitabine against fluorouracil-sensitive and -resistant tumors
14. Mechanisms and therapeutic implications of angiogenesis
15. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts
16. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
17. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts
18. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitibine (Xeloda) in human cancer xenografts
19. Phase I and pharmalogic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
20. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
21. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine
22. Clinical pharmacokinetics of capecitabine
23. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients
24. A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14 C-labelled drug
25. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites
26. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients
27. Warfarin-5-FU interaction: A consecutive case series
28. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
29. Oral capecitabine compared with intravenous 5-fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study
30. A phase II study of Xeloda (capecitabine) in patients with metastatic colorectal cancer demonstrating progression on 5-FU therapy
31. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
32. Extended phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer
33. Phase I study of capecitabine with simultaneous radiotherapy in rectal cancer
34. CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (MCRC): Preliminary results of a phase I/II study
35. Dose escalation and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan (CPT-11) in gastro-intestinal tumours
36. Capecitabine in combination with oxaliplatin as first-line therapy for patients with advanced or metastatic colorectal cancer: Preliminary results of an international multi-centre phase II study
37. Reporting results of cancer treatment
38. Capecitabine as first-line treatment for colorectal cancer (CRC): Integrated results of 1207 patients (pts) from 2 randomized, phase III studies
39. Capecitabine as first-line treatment for metastatic colorectal cancer (CRC): Integrated results of 1207 patients (pts) from 2 randomized, phase III studies
40. A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors
41. Effective dose-modification (DM) scheme for the management of toxicities with capecitabine therapy: Data from metastatic colorectal cancer (mCRC) phase III trials
42. Severe ocular irritation and corneal deposits associated with capecitabine use
43. Medical resource use in a phase III trial (SO 14796) of Xeloda® (capecitabine) in previously untreated advanced/metastatic colorectal cancer
44. Oral fluoropyrimidines
45. Patient preferences for oral versus intravenous palliative chemotherapy
46. Raltitrexed: A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer
47. Irinotecan: A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer
48. Oxaliplatin: A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies
49. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer